Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02370784 · ClinicalTrials.gov registry record · Phase 2
Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma
A Phase 2 study, sponsored by Robyn T. Domsic, MD, MPH.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT02370784 is a Phase 2 study that has completed, run by Robyn T. Domsic, MD, MPH. The registered enrollment target is 24 participants.
The verdict
NCT02370784, a Phase 2 study, has completed, sponsored by Robyn T. Domsic, MD, MPH.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about the effect atorvastatin on blood vessel function and Raynaud symptoms in patients with early diffuse systemic sclerosis. Systemic sclerosis is a disease characterized by blood vessel injury, immune system activation and fibrosis. Blood vessel injury is thought to be important early in the disease. Blood vessel complications of systemic sclerosis include Raynaud phenomena, finger and toe ulcers, and pulmonary hypertension. While atorvastatin reduces cholesterol, it is recognized to have many effects beyond cholesterol reduction. These include improvement of blood vessel function and reduction of fibrosis. We hypothesize that treatment with atorvastatin over 16 weeks will improve blood vessel function and Raynaud symptom in patients with early diffuse systemic sclerosis. We hope that by targeting therapy early in the disease we may delay blood vessel changes and improve Raynaud symptoms.
Interventions
- DRUG Placebo
- DRUG atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-02 |
| Est. Completion | 2019-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02370784
The ClinicalTrials.gov registry entry for NCT02370784 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Robyn T. Domsic, MD, MPH, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02370784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02370784 about?
NCT02370784 is a clinical study titled "Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma". The purpose of this study is to learn about the effect atorvastatin on blood vessel function and Raynaud symptoms in patients with early diffuse systemic sclerosis. Systemic sclerosis is a disease characterized by blood vessel injury, immune system activation and fibrosis. Blood vessel injury is th...
What is the current status of trial NCT02370784?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2015-02. Estimated completion is 2019-12-15.
What interventions are being tested in trial NCT02370784?
The interventions under investigation include: Placebo (DRUG), atorvastatin (DRUG).
Who is sponsoring clinical trial NCT02370784?
This trial is sponsored by Robyn T. Domsic, MD, MPH, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.